Skip to content
sugarisadrug.com
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

Category: Diabetes

1321-OR: Superior Quality of Weight Loss with a Novel Unimolecular Tetra-Agonist Peptide Targeting GLP-1, GIP, Amylin, and Calcitonin Receptors vs. Tirzepatide and Cagrisema in Diet-Induced Obese Rats

June 10, 2026 by sugaradmin

Introduction and Objective: The rising prevalence of obesity and related comorbidities highlights the need for safe, effective, and durable therapies. We evaluated PTT-A, a novel long-acting tetra-agonist targeting GLP-1, GIP, amylin, and calcitonin receptors, in diet-induced obese (DIO) rats and compared its efficacy with tirzepatide and CagriSema.Methods: DIO rats received PTT-A (10 or 30 nmol/kg), […]

Read More
DiabetesLeave a Comment on 1321-OR: Superior Quality of Weight Loss with a Novel Unimolecular Tetra-Agonist Peptide Targeting GLP-1, GIP, Amylin, and Calcitonin Receptors vs. Tirzepatide and Cagrisema in Diet-Induced Obese Rats

1282-OR: Major Adverse Limb Events with Tirzepatide vs. Injectable Semaglutide in Adults with Type 2 Diabetes and Peripheral Artery Disease

June 10, 2026 by sugaradmin

Introduction and Objective: Peripheral artery disease (PAD) increases the risk for amputations and limb-threatening events in people with type 2 diabetes (T2D). Tirzepatide and injectable semaglutide are associated with improved limb outcomes. However, real-world comparative outcomes are unknown.Methods: This retrospective cohort study used the TriNetX real-world global database across 112 healthcare organizations with over 130 […]

Read More
DiabetesLeave a Comment on 1282-OR: Major Adverse Limb Events with Tirzepatide vs. Injectable Semaglutide in Adults with Type 2 Diabetes and Peripheral Artery Disease

1301-OR: Mitraa-T2D: Comparative Real-World Outcomes of a Digital Conversational Support Tool on Engagement, Adherence, and Glycemic Control in Adults with Type 2 Diabetes

June 10, 2026 by sugaradmin

Introduction and Objective: Limited patient engagement and suboptimal adherence remain major barriers in type 2 diabetes management. Digital conversational support tools may reinforce self-care between clinic visits. This study aimed to determine whether use of a digital conversational support tool, as an adjunct to usual care, is associated with improved behavioral and glycemic outcomes compared […]

Read More
DiabetesLeave a Comment on 1301-OR: Mitraa-T2D: Comparative Real-World Outcomes of a Digital Conversational Support Tool on Engagement, Adherence, and Glycemic Control in Adults with Type 2 Diabetes

1305-OR: Emerging Type 1 Diabetes Screening and Intervention Programs: Insights from 63 Centers in the T1D Exchange Quality Improvement (Type 1 DiabetesX-QI) Collaborative

June 9, 2026 by sugaradmin

Introduction and Objective: Early stage T1D screening programs in routine clinical care are in their infancy. With the availability of teplizumab, a disease-modifying therapy that delays progression to Stage 3 T1D, there is an urgent need to reimagine T1D care. Understanding current screening practices can inform implementation strategies and identify gaps as the field moves […]

Read More
DiabetesLeave a Comment on 1305-OR: Emerging Type 1 Diabetes Screening and Intervention Programs: Insights from 63 Centers in the T1D Exchange Quality Improvement (Type 1 DiabetesX-QI) Collaborative

1330-OR: Quantifying the Kinetics of Proglucagon-Derived Peptide Fragments Using Somatostatin and Glucagon Infusion

June 9, 2026 by sugaradmin

Introduction and Objective: Prohormone convertase enzymes within α-cells process proglucagon into several peptides. These include glicentin (GLY), major proglucagon fragment (MPGF), and oxyntomodulin (OXM). Assessing their in vivo secretion (SR) can provide insights on α-cell function in health and disease. However, estimating their SR from peripheral concentrations requires knowledge of their kinetics. Here we propose […]

Read More
DiabetesLeave a Comment on 1330-OR: Quantifying the Kinetics of Proglucagon-Derived Peptide Fragments Using Somatostatin and Glucagon Infusion

1283-OR: Feasibility and Acceptability of Deaf Diabetes Can Together (DEDICATE): A Diabetes Self-Management Education and Support Intervention in American Sign Language

June 9, 2026 by sugaradmin

Introduction and Objective: This pilot study aimed to examine feasibility and acceptability of a telehealth DSMES intervention, Deaf Diabetes Can Together (DEDICATE), to support Deaf and hard of hearing (DHH) adults with type 1 and type 2 diabetes.Methods: Diabetes DHH Participants completed a 10- to 12-week multicomponent telehealth intervention in ASL consisting of DSMES ASL […]

Read More
DiabetesLeave a Comment on 1283-OR: Feasibility and Acceptability of Deaf Diabetes Can Together (DEDICATE): A Diabetes Self-Management Education and Support Intervention in American Sign Language

1329-OR: Interlaboratory Validation and Method Comparison of a Novel LC-MS/MS Assay for Glucagon and Oxyntomodulin

June 9, 2026 by sugaradmin

Introduction and Objective: The quantification of plasma glucagon and oxytomodulin is important in the assessment of alpha-cell function, which is impaired in patients with diabetes. We aimed to develop, validate, and transfer between laboratories a novel assay that uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the sensitive and specific measurement of these highly homologous hormones.Methods: […]

Read More
DiabetesLeave a Comment on 1329-OR: Interlaboratory Validation and Method Comparison of a Novel LC-MS/MS Assay for Glucagon and Oxyntomodulin

1315-OR: Escaping Rejection: PD–L1/HVEM–Engineered β-Cells for Durable Transplant Survival

June 9, 2026 by sugaradmin

Introduction and Objective: Islet allo-transplantation can potentially cure type 1 diabetes (T1D), but immune rejection and systemic immunosuppression remain key challenges. Inspired by cancer immunotherapy, we hypothesized that engineering islet cells with checkpoint ligands could induce transplant tolerance. Our lab previously showed that autologous β cells reverse autoimmunity in NOD mice. Here, we demonstrate proof […]

Read More
DiabetesLeave a Comment on 1315-OR: Escaping Rejection: PD–L1/HVEM–Engineered β-Cells for Durable Transplant Survival

1320-OR: SPID-Engineered Long-Acting GIPR Antagonist Antibody for Weight Maintenance and Glycemic Recovery

June 9, 2026 by sugaradmin

Introduction and Objective: Obesity is a chronic disease requiring lifelong management, yet peptide agonists face high discontinuation and rebound weight gain due to dosing burdens. Improving therapeutic persistence requires long-acting agents optimized for weight maintenance. Leveraging antibody-based half-life extension, we developed a potent GIPR antagonist. This study evaluates its cellular potency and metabolic durability in […]

Read More
DiabetesLeave a Comment on 1320-OR: SPID-Engineered Long-Acting GIPR Antagonist Antibody for Weight Maintenance and Glycemic Recovery

1314-OR: Allogeneic Islets Are Rejected by Diabetic NOD Mice while Allogeneic Neo-Islets, 3D Organoids of Islet and Mesenchymal Stromal Cells, Durably Cure Their Type 1 Diabetes without Antirejection Drugs: Mechanisms

June 9, 2026 by sugaradmin

Introduction and Objective: T1D & T2D Dysglycemia impairs intrinsic Mesenchymal Stromal Cells’ (MSCs) protective & regenerative functions including those of pancreatic Islet-intrinsic MSCs. This accelerates b-Cell loss. Replacing MSCs at high numbers within Neo-Islets (NIs) corrects the dysfunction. The MSC component in NIs exerts trophic, anti-inflammatory, auto- and allo-immune modulatory actions (survival, angiogenic, anti-fibrotic). We […]

Read More
DiabetesLeave a Comment on 1314-OR: Allogeneic Islets Are Rejected by Diabetic NOD Mice while Allogeneic Neo-Islets, 3D Organoids of Islet and Mesenchymal Stromal Cells, Durably Cure Their Type 1 Diabetes without Antirejection Drugs: Mechanisms

Posts navigation

Older posts
Newer posts

Recent Posts

  • Management of dysglycemia in critically ill adults: current evidence, clinical practice and future directions
  • What's Next—Amylin-based Therapies
  • After GLP-1s Quit Working, He Lost 80 Pounds with a Simple Procedure
  • Perimenopause: Can Regular Exercise Improve Your Symptoms?
  • GLP-1 Side Effects vs. Benefits: Real Patient Experiences

Recent Comments

  • A WordPress Commenter on SUCROSE: “PURE” ENERGY AT A PRICE

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • November 2024
  • October 2024
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • May 2017

Categories

  • Celebrity Health
  • Diabetes
  • Food Choices
  • Fructose
  • General Sugar
  • Glucose
  • Health News
  • Insulin
  • Mental Health
  • Natural Unrefined Sugar
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Sucrose
  • Sugar Science

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

© 2026 Sugar is a DRUG | Sugar Addiction Awareness